The WAR approved the pharmacotherapeutic report of the medicine mirabegron (Betmiga). Its therapeutic value was determined via comparison with tolterodine (muscarinic receptor antagonist). They reached the following conclusions: the therapeutic value of mirabegron for the symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence, as may occur in adult patients with overactive bladder syndrome, is equal to that of tolterodine.